Skip to main content

Table 2 Correlation of SOX2 score and clinicopathological parameters

From: Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma

  

SOX2

 
 

N total

Negative Score 0

Positive Score 1-3

p-value

Tumor size

    

   pT1

59

46 (78%)

13 (22%)

0.073

   pT2 to pT4

27

16 (59%)

11 (41%)

 

Nodal status

    

   Node-negative

62

44 (71%)

18 (29%)

0.789

   Node-positive

23

17 (74%)

6 (26%)

 

Histology

    

   Ductal

76

49 (73%)

18 (27%)

 

   Lobular

11

10 (91%)

1 (10%)

0.053

   Others

8

5 (38%)

5 (63%)

 

Grading

    

   I-II

60

45 (75%)

15 (25%)

0.361

   III

26

17 (65%)

9 (35%)

 

Lymphovasc. inv.

    

   Negative

63

48 (76%)

15 (24%)

0.161

   Positive

23

14 (61%)

9 (39%)

 

ER status

    

   Negative

17

12 (71%)

5 (29%)

0.877

   Positive

69

50 (73%)

19 (28%)

 

PR status

    

   Negative

22

16 (73%)

6 (27%)

0.939

   Positive

64

46 (72%)

18 (28%)

 

HER2

    

   Negative

75

55 (73%)

20 (27%)

0.503

   Positive

11

7 (64%)

4 (36%)

 

Subtype

    

   Luminal A/B *

73

53 (73%)

20 (27%)

 

   HER2 subtype

6

4 (67%)

2 (33%)

0.952

   Triple negative

7

5 (71%)

2 (29%)

 
  1. *Luminal A tumors are defined as tumors with expression of one or both hormone receptors without overexpression of Her2; Luminal B tumors express one or both hormone receptors and show also Her2 overexpression.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us